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Background: Gemcitabine is a pyrimidine nucleoside analog that is a commonly used chemotherapeutic agent for
unresectable or recurrent biliary tract cancer (BTC). Several molecules involved in gemcitabine metabolism,
including human equilibrative nucleoside transporter (hENT1), deoxycytidine kinase (dCK), and ribonucleotide
reductase subunit M1 (RRM1), have been investigated as predictive biomarkers of gemcitabine efficacy, mostly in
pancreatic cancer. The aim of this study is to clarify which biomarker is the most reliable among hENT1, dCK, and
RRM1 to predict survival in patients with advanced BTC treated with gemcitabine alone.
Methods: The analysis was performed on samples from 28 patients with unresectable or recurrent BTC who were
treated with gemcitabine alone as first-line therapy. The starting date of overall survival (OS) and progression-free
survival (PFS) was defined as the date of first treatment with gemcitabine. Intratumoral hENT1, dCK, and RRM1
expressions were examined by immunohistochemistry.
Results: The expressions of hENT1, dCK, and RRM1 had no significant relationships with age, gender, primary tumor
site, recurrence/unresectable, or histological type. Among the three molecules, only hENT1 expression was a
significant factor affecting OS and PFS in univariate analysis; OS was 11.4 months for high hENT1 expression versus
5.7 months for low, P = 0.0057; PFS was 7.7 months for high versus 2.5 months for low, P = 0.0065. Multivariate
analyses also identified hENT1 expression as an independent predictive factor for OS.
Conclusions: hENT1 is the most reliable predictive marker of survival in patients with advanced BTC treated with
gemcitabine.
Keywords: Biliary tract cancer, Deoxycytidine kinase, Gemcitabine, Human equilibrative nucleoside transporter 1,
Ribonucleotide reductase subunit M1Background
Biliary tract cancer (BTC) is relatively rare, but its inci-
dence is increasing worldwide. The prevalence is much
higher in East Asia and Latin America than in Europe and
the United States [1,2]. Although a complete surgical
resection is the only curative modality, most patients are
not eligible for surgery because of the advanced stage of
disease at diagnosis. Moreover, even patients who undergo* Correspondence: ramano@med.osaka-cu.ac.jp
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reproduction in any medium, provided the ora surgical resection often have a recurrence of the disease.
The outcome for patients with unresectable or recurrent
BTC is dismal and their median survival is usually under 1
year [3]. Most patients with unresectable or recurrent
BTC are therefore candidates for palliative chemotherapy.
Gemcitabine (2′,2′-difluorodeoxycytidine), a deoxycyti-
dine analog that inhibits DNA replication and repair, is
the most effective single agent in advanced BTC. Because
gemcitabine is hydrophilic and does not cross the plasma
membrane by passive diffusion, its cellular uptake requires
the presence of a specialized plasma membrane nucleosideLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Recurrence after surgery 22
Unresectable 6
Figure 1 Immunohistochemical analysis of hENT1, dCK, and
RRM1 expressions in biliary tract cancer. Representative
immunohistochemical results. Human equilibrative nucleoside
transporter 1 (hENT1): (A) high staining and (B) low staining.
Deoxycytidine kinase (dCK): (C) high staining and (D) low staining.
Ribonucleotide reductase subunit M1 (RRM1): (E) high staining and
(F) low staining. Magnification × 200, scale bar = 100 μm.
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mainly by human equilibrative transporter 1 (hENT1).
After intracellular entry, gemcitabine is phosphorylated by
deoxycytidine kinase (dCK) to its active diphosphate and
triphosphate in a rate-limiting step. The incorporation of
gemcitabine triphosphate into DNA, leading to chain ter-
mination, is a major mechanism underlying the cytotoxicity
of gemcitabine [5,6]. In addition, gemcitabine diphosphate
inhibits ribonucleotide reductase (RRM1, RRM2), causing a
decrease in the cellular pool of deoxycytidine triphosphate
that competes with gemcitabine triphosphate for incor-
poration into DNA [7].
Recent investigations using cell lines or surgical speci-
mens have revealed that these proteins were predictors for
the efficacy of gemcitabine treatment. In particular, hENT1
expression has been evaluated as a predictive marker for
gemcitabine chemotherapy in patients with pancreatic can-
cer. In vitro studies demonstrated that deficiency of hENT1
conferred resistance to gemcitabine and hENT1 expression
was positively associated with gemcitabine chemosensitivity
[4,8,9]. In patients with pancreatic cancer from a random-
ized phase III RTOG 9704 study, hENT1 expression was
associated with increased overall survival (OS) and disease-
free survival in patients who received adjuvant gemcitabine
chemotherapy, but not in those who received 5-fluorouracil
[10]. Other retrospective studies have also demonstrated
the predictive and prognostic value of hENT1 in patients
with pancreatic cancer [11,12].
Other key enzymes involved in gemcitabine metabo-
lism have also been evaluated as predictive markers. In
pancreatic cancer, high dCK expression was identified
as an independent prognostic factor in patients who re-
ceived adjuvant gemcitabine therapy [13]. In contrast,
high expression of RRM1 was associated with poor
survival after gemcitabine treatment in patients with
recurrent pancreatic cancer [14,15].
There are thus many reports about predictive markers
for the efficacy of gemcitabine in pancreatic cancer, but
there are limited data available on the predictive value of
these markers in BTC. Based on the importance of the bio-
markers involved in gemcitabine metabolism, we assessed
the expressions of three key molecules (hENT1, dCK, and
RRM1) in tumor samples from 28 patients with advanced
BTC who received first-line gemcitabine monotherapy. To
our knowledge, this study is the first to examine the pre-
dictive aspect of hENT1, dCK, and RRM1 for gemcitabine-
treated advanced BTC in the same clinical samples. The
aim of this study was to investigate the association between
the expressions of these proteins and prognosis.
Methods
Subjects
A total of 28 patients with histopathologically confirmed
unresectable or postoperative recurrent BTC treatedwith first-line gemcitabine monotherapy at Osaka City
University Hospital between October 2006 and April
2011 were included in this study. Adjuvant chemother-
apy including gemcitabine was not given to these pa-
tients. BTC comprised extrahepatic bile duct cancer and
gallbladder cancer. Intrahepatic bile duct cancer was ex-
cluded because unresectable or recurrent intrahepatic
bile duct cancer patients in our institution were treated
Table 2 Clinicopathological characteristics based on hENT1, dCK, and RRM1 expression for advanced biliary tract
cancer subjects














Extrahepatic bile duct 7 11 1.000 10 8 0.254 8 10 0.689
Gallbladder 4 6 3 7 3 7
Recurrence or unresectable
Recurrence after surgery 9 13 1.000 9 13 0.372 7 15 0.174
Unresectable 2 4 4 2 4 2
Histological type
Well/moderately 9 12 0.668 11 10 0.396 9 12 0.668
Poor 2 5 2 5 2 5
hENT1 expression
High – – – 7 10 0.700 6 11 0.701
Low – – 6 5 5 6
dCK expression
High * * * – – – 2 13 0.006
Low * * – – 9 4
dCK, deoxycytidine kinase; hENT1, human equilibrative nucleoside transporter; RRM1, ribonucleotide reductase subunit M1. *Same as above line
(hENT1 expression).
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infusion of 5-fluorouracil. Subject demographics and
clinical characteristics are listed in Table 1. In six sub-
jects with unresectable cases, one had liver metastasis and
five had peritoneal disseminations. The median OS from
initiation of gemcitabine chemotherapy was 10.0 months
for all 28 subjects. All tumor samples were obtained priorFigure 2 Sample distribution for high hET1, dCK, and RRM1
expression in unresectable/recurrent biliary tract cancer. The
number in each area is the number of samples with high expression
of these biomarkers. dCK, deoxycytidine kinase; hENT1, human
equilibrative nucleoside transporter; RRM1, ribonucleotide reductase
subunit M1.to gemcitabine chemotherapy. For all six unresectable tu-
mors, the biopsy specimens were obtained from metastatic
lesions during probe laparotomies. Chemotherapy consisted
of intravenous gemcitabine infusion using the following
protocols: the gemcitabine standard protocol (1,000 mg/m2
on days 1, 8, and 15 every 4 weeks). When the patients
treated with weekly gemcitabine presented a grade 3
hematological adverse event or a grade 2 nonhematological
adverse event defined by Common Terminology Criteria
for Adverse Events version 3.0, a biweekly protocol (1,000
mg/m2 on days 1 and 15 every 4 weeks) was given to them.
Informed consent to use the specimens for this study
according to the institutional rules of the hospital was
obtained from all subjects.
Immunohistochemistry of the specimens
Biomarker (hENT1, dCK, and RRM1) expression in BTC
specimens was determined by immunohistochemical
staining using the avidin–biotin–peroxidase complex
method. In brief, the 4 μm thick formalin-fixed, paraffin-
embedded sections were deparaffinized in xylene and
decreasing concentrations of ethanol. The slides were
treated with 3% hydrogen peroxide in methanol for 15
minutes to block endogenous peroxidase activity. To re-
trieve the antigenicities, slides were heated for 10 minutes
at 105°C by autoclave in Target Retrieval Solution (Dako
Co., Carpinteria, CA, USA) and cooled at room tempe-
rature for at least 30 minutes. Incubation was performed
in a humidified chamber overnight at 4°C with anti-
Table 3 Univariate analysis for overall survival by log-
rank test




Extrahepatic bile duct 18 11.4 0.2423
Gallbladder 10 9.2
Recurrence or unresectable
Recurrence 22 10.0 0.6183
Unresectable 6 9.2
Histological type
Well/moderately 21 10.0 0.9202
Poor 7 11.4
hENT1 expression
Low 11 5.7 0.0057
High 17 11.4
dCK expression
Low 13 9.2 0.3725
High 15 11.4
RRM1 expression
Low 11 10.2 0.5941
High 17 10.0
dCK, deoxycytidine kinase; hENT1, human equilibrative nucleoside transporter;
RRM1, ribonucleotide reductase subunit M1.
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IL, USA) at a 1:100 dilution and with anti-RRM1 mouse
mAb (Proteintech) at a 1:100 dilution. The final incuba-
tion was for 2 hours at room temperature with anti-dCK
rabbit polyclonal antibody (LSBio, Seattle, WA, USA) at a
1:24 dilution (20 μg/ml); 3,3′-diaminobenzidine (Nichirei,
Tokyo, Japan) was used as a chromogen. The sections
were rinsed, counterstained with hematoxylin, dehydrated
through graded alcohol and xylene, and coverslipped.
Negative controls processed by omitting the primary anti-
bodies were included for each staining.
Immunohistochemical evaluation
As previously reported [10], the scoring for hENT1 was
based on relative intensities of the BTC staining with
reference to the normally strong hENT1 staining withinTable 4 Multivariate analysis for overall survival using variab
Variable Comparison
Primary tumor site Gallbladder vs. extrahepatic bile du
Recurrence or unresectable Unresectable vs. recurrence
Histological type Poor vs. well/moderately
hENT1 expression High vs. low
dCK expression High vs. low
CI, confidence interval; dCK, deoxycytidine kinase; hENT1, human equilibrative nuclelymphocytes. These internal references were used as
internal positive controls between slides and samples, as
well as for the staining procedure. Tumor tissue staining
was then evaluated by comparison with the internal con-
trols. A score of high hENT1 staining was given for
weak and/or strong reactivity in >50% of neoplastic cells.
A score of low hENT1 staining was given if there was
no staining in >50% of cells. Scoring for dCK and RRM1
was done in the same manner on the basis of the relative
intensities of tumor staining with reference to the in-
ternal controls. The internal control for dCK was pro-
vided by lymphocyte staining as previously described
[13]. Plasma and stromal cells showed positive RRM1
staining for cytoplasm, which was considered the in-
ternal control [16]. Staining grade was evaluated by two
investigators without previous knowledge of the clinical
characteristics and outcomes.Statistical analysis
All subjects were classified into high and low expression
groups according to hENT1, dCK, and RRM1 staining.
The significance of the correlation between expressions
and clinicopathological characteristics was assessed by the
chi-square test (Fisher’s exact test). Survival probabilities
were calculated using the Kaplan–Meier method, and the
log-rank test was used for univariate survival analysis. If
OS was defined as the period from the date of first diagno-
sis of BTC, various factors such as operative curability and
resectability might affect the survival time. The purpose of
this study was focused on the impact of gemcitabine
sensitivity-related gene products. OS was therefore mea-
sured from the date of first treatment with gemcitabine to
the date of death or last follow-up evaluation. Progression-
free survival (PFS) according to clinical judgment was mea-
sured from the date of first treatment with gemcitabine to
the date of first progression or death without any progre-
ssive disease. Data on survivors were censored at the last
follow-up. We also performed a multivariate analysis using
Cox proportional hazards modeling to measure correla-
tions between clinicopathological variables and OS. For all
tests, two-sided P values <0.05 were defined as statistically
significant. The SPSS software program (SPSS Japan,
Tokyo, Japan) was used for the analysis.les including hENT1 and dCK
HR 95% CI P value
ct 1.617 0.596 to 4.389 0.345
1.707 0.511 to 5.700 0.384
1.117 0.354 to 3.519 0.851
0.270 0.097 to 0.748 0.012
0.778 0.284 to 2.132 0.625
oside transporter; HR, hazard ratio.
Table 5 Multivariate analysis for overall survival using variables including hENT1 and RRM1
Variable Comparison HR 95% CI P value
Primary tumor site Gallbladder vs. extrahepatic bile duct 2.136 0.751 to 6.078 0.155
Recurrence or unresectable Unresectable vs. recurrence 3.109 0.860 to 11.238 0.084
Histological type Poor vs. well/moderately 0.732 0.235 to 2.282 0.591
hENT1 expression High vs. low 0.220 0.077 to 0.629 0.005
RRM1 expression High vs. low 2.315 0.773 to 6.928 0.133
CI, confidence interval; hENT1, human equilibrative nucleoside transporter; HR, hazard ratio; RRM1, ribonucleotide reductase subunit M1.
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Immunostaining and subject background
Examples of high and low tumor staining are shown in
Figure 1. hENT1 immunostaining was localized predo-
minantly in the membrane, although occasional cytoplas-
mic staining was also observed. dCK immunostaining was
located in the cytoplasm and the nucleus and RRM1 stain-
ing was seen in the cytoplasm. Of the 28 tumors, hENT1
was high in 17 (60.7%), dCK in 15 (53.6%), and RRM1 in
17 (60.7%). The relationship between clinicopathological
factors and the expressions of hENT1, dCK, and RRM1 is
summarized in Table 2. There were no significant diffe-
rences in primary tumor site, recurrence/unresectable, or
histological type. Among hENT1, dCK, and RRM1 expre-






Extrahepatic bile duct 18 4.6 0.2551
Gallbladder 10 3.4
Recurrence or unresectable
Recurrence 22 3.9 0.7073
Unresectable 6 7.4
Histological type
Well/moderately 21 4.4 0.7255
Poor 7 5.2
hENT1 expression
Low 11 2.5 0.0065
High 17 7.7
dCK expression
Low 13 4.6 0.8076
High 15 3.7
RRM1 expression
Low 11 7.4 0.1349
High 17 2.5
dCK, deoxycytidine kinase; hENT1, human equilibrative nucleoside transporter;
RRM1, ribonucleotide reductase subunit M1.observed between dCK and RRM1. Figure 2 shows the
distribution of high expression of the three biomarkers.
Survival analysis according to hENT1, dCK, and RRM1
expression
Univariate analysis showed that the expression of hENT1
was associated significantly with OS; however, primary
tumor site, recurrence/unresectable, histological type, dCK,
and RRM1 were not associated with OS (Table 3). Con-
founding factors (dCK and RRM1) could not be analyzed
simultaneously in a multivariate analysis. Therefore, each
of dCK and RRM1 was added to the multivariate analysis
with primary tumor site, recurrence or unresectable, his-
tological type, and hENT1 expression. The results de-
monstrated that high hENT1 expression alone was an
independent prognostic predictor (Tables 4 and 5). Uni-
variate analysis for PFS demonstrated significant associ-
ation between hENT1 and PFS. Other variables including
dCK and RRM1 were not related to PFS (Table 6).
Discussion
hENT1 is the primary gatekeeper for intracellular uptake
of gemcitabine, and both dCK and RRM1 are related to
gemcitabine metabolism after intracellular entry. Marechal
and colleagues recently investigated the predictive value of
hENT1, dCK, and RRM1 in patients with pancreatic can-
cer treated with adjuvant gemcitabine chemotherapy and
demonstrated that both hENT1 and dCK expressions
were powerful predictive markers [17]. There have been
several studies on the impact of single gemcitabine
sensitivity-related gene products (such as hENT1, dCK,
and RRM1) on gemcitabine-based treatment effects in
BTC. These previous investigations were based on immu-
nohistochemistry. To our knowledge, there have been no
studies on the association between gemcitabine effects
and mRNA expression of gemcitabine sensitivity-related
genes in BTC. Our study was performed using the immu-
nohistochemical method because the frozen tissues of BTC
studied here were not kept. The originality of our study is
that we observed all of these biomarkers simultaneously in
patients with BTC treated only with gemcitabine.
We analyzed hENT1, dCK, and RRM1 expression
using immunohistochemical analysis to determine the
prognostic value in patients with advanced BTC treated
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dictive marker for gemcitabine chemotherapy in ad-
vanced BTC. Patients with a high level of tumor hENT1
had a statistically significant longer OS and PFS than
those with low expression. Our study also demonstrated
that high hENT1 expression was an independent prog-
nostic factor in patients with advanced BTC, treated
with first-line gemcitabine monotherapy.
There are a few papers on the prognostic value of
hENT1 in patients with BTC treated with gemcitabine.
Santini and colleagues reported that an immunohisto-
chemical evaluation of intratumoral hENT1 expression
might be useful in predicting the clinical outcome of
gemcitabine-based chemotherapies in 31 patients with
advanced BTC (extrahepatic biliary tract, intrahepatic
biliary tract, gall bladder, and ampulla). However, they
were unable to find a statistically significant difference in
OS [18]. Borbath and colleagues reported that high
expression of hENT1 was independently associated with
prolonged PFS and OS in 26 patients with locally ad-
vanced or metastatic extrahepatic and intrahepatic
cholangiocarcinoma who were treated with gemcitabine
[19]. Kobayashi and colleagues recently demonstrated that
high hENT1 expression was associated with prolonged
OS in resected extrahepatic and intrahepatic cholangioca-
rcinoma treated with gemcitabine-based adjuvant chemo-
therapy [20]. The primary sites of BTC in these studies
and ours varied. However, the positive survival impact of
hENT1 on BTC treated with gemcitabine-based chemo-
therapy in these studies was concordant. On the other
hand, the potential prognostic value of hENT1 expression
in patients with BTC who did not receive gemcitabine
chemotherapy is unclear. Although we investigated the ex-
pression of hENT1 in 39 patients with advanced BTC
who did not receive gemcitabine, no significant survival
difference was observed between patients with high and
low hENT1 (data not shown).
RRM1 have been reported previously as predictive
markers for gemcitabine in pancreatic cancer, although
there are few published studies evaluating their value in
BTC. Nakamura and colleagues reported that high
RRM1 expression had a positive association with poor
prognosis in 10 patients with advanced BTC treated with
gemcitabine-based chemotherapy with or without radi-
ation [21]. In the current study, the expression of RRM1
was not associated with a prognosis. The differing re-
sults for RRM1 impact on the survival of patients with
BTC between Nakamura and colleagues’ study and ours
might be due to the different treatment modalities.
An abundance of dCK is commonly known to be asso-
ciated with gemcitabine sensitivity in pancreatic cancer.
There has been no paper describing dCK expression in
patients with BTC. In the current study, there was sig-
nificant correlation between dCK and RRM1 expression.The reason for this is unclear, but both proteins are key
enzymes related to deoxycytidine metabolism.
The limitation of this study is that it was a retrospective
evaluation. Prospective investigation including an ad-
equate number of samples is needed to confirm the im-
portance of gemcitabine sensitivity-related gene products
in patients with advanced BTC treated with gemcitabine.
In addition, the relations between gemcitabine effects in
BTC and other gemcitabine sensitivity-related gene pro-
ducts such as RRM2, cytidine deaminase, human concen-
trative nucleoside transporter 1 and 3, 5′-nucleotidase, and
deoxycytidylate deaminase are remained to be elucidated
for further investigations.
Conclusions
In this study, high hENT1 expression was a reliable
predictive marker of survival in patients with recurrent
or unresectable BTC who received gemcitabine chemo-
therapy alone.
Abbreviations
BTC: Biliary tract cancer; dCK: Deoxycytidine kinase; hENT1: Human
equilibrative nucleoside transporter 1; mAb: Monoclonal antibody;
OS: Overall survival; PFS: Progression-free survival; RRM1: Ribonucleotide
reductase subunit M1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM carried out almost studies and performed the manuscript. RA and NY
supported with design and interpretation of this study. Statistical analysis
was performed by AM and KK. MY and BN helped to draft the manuscript.
Overall supervision of the manuscript was completed by KH. All authors read
and approved the final manuscript.
Received: 12 December 2012 Accepted: 12 May 2013
Published: 27 May 2013
References
1. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C:
Epidemiology of biliary tract cancers: an update. Ann Oncol 2009,
20:146–159.
2. Matsuda T, Marugame T: International comparisons of cumulative risk of
gallbladder cancer and other biliary tract cancer, from Cancer Incidence
in Five Continents Vol. VIII. Jpn J Clin Oncol 2007, 37:74–75.
3. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a
pooled analysis of clinical trials. Br J Cancer 2007, 96:896–902.
4. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR,
Cass CE: Functional nucleoside transporters are required for gemcitabine
influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998,
58:4349–4357.
5. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol
1995, 22:19–25.
6. van Haperen VWR, Veerman G, Vermorken JB, Peters GJ: 2′,2′-Difluoro-
deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour
cell lines. Biochem Pharmacol 1993, 46:762–766.
7. Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: preclinical
pharmacology and mechanisms of action. Semin Oncol 1996, 23:3–15.
8. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M,
Izawa T, Mizukami Y, Okumura T, Kohgo Y: Gemcitabine chemoresistance
and molecular markers associated with gemcitabine transport and
metabolism in human pancreatic cancer cells. Br J Cancer 2007,
96:457–463.
Murata et al. World Journal of Surgical Oncology 2013, 11:117 Page 7 of 7
http://www.wjso.com/content/11/1/1179. Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y,
Endo I, Togo S, Danenberg PV, Shimada H: Human equilibrative
nucleoside transporter 1 is associated with the chemosensitivity of
gemcitabine in human pancreatic adenocarcinoma and biliary tract
carcinoma cells. Oncol Rep 2007, 17:1201–1205.
10. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson
AB, Macdonald J, Cass CE, Dicker AP, Mackey JR: Human equilibrative
nucleoside transporter 1 levels predict response to gemcitabine in
patients with pancreatic cancer. Gastroenterology 2009, 136:187–195.
11. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass
C, Lai R, Mackey JR: The absence of human equilibrative nucleoside
transporter 1 is associated with reduced survival in patients with
gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004,
10:6956–6961.
12. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C,
Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F,
Danesi R: Transcription analysis of human equilibrative nucleoside
transporter-1 predicts survival in pancreas cancer patients treated with
gemcitabine. Cancer Res 2006, 66:3928–3935.
13. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE,
Salmon I, Deviere J, Van Laethem JL: Deoxycitidine kinase is associated
with prolonged survival after adjuvant gemcitabine for resected
pancreatic adenocarcinoma. Cancer 2010, 116:5200–5206.
14. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki
M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K,
Umeshita K, Sakon M, Monden M: Involvement of ribonucleotide
reductase M1 subunit overexpression in gemcitabine resistance of
human pancreatic cancer. Int J Cancer 2007, 120:1355–1363.
15. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S,
Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y,
Bepler G: Significance of RRM1 and ERCC1 expression in resectable
pancreatic adenocarcinoma. Oncogene 2009, 28:2903–2909.
16. Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K:
Ribonucleotide reductase subunit M1 is a possible chemoresistance
marker to gemcitabine in biliary tract carcinoma. Oncol Rep 2008,
20:279–286.
17. Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K,
Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C,
Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP,
Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL: Levels of
gemcitabine transport and metabolism proteins predict survival times of
patients treated with gemcitabine for pancreatic adenocarcinoma.
Gastroenterology 2012, 143:664–674. e1-e6.
18. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V,
Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey
J, Falcone A, Tonini G: Human equilibrative nucleoside transporter 1
(hENT1) levels predict response to gemcitabine in patients with biliary
tract cancer (BTC). Curr Cancer Drug Targets 2011, 11:123–129.
19. Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H, Sempoux
C: Human equilibrative nucleoside transporter 1 (hENT1) expression is a
potential predictive tool for response to gemcitabine in patients with
advanced cholangiocarcinoma. Eur J Cancer 2012, 48:990–996.
20. Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda
T: Human equilibrative nucleoside transporter 1 expression predicts
survival of advanced cholangiocarcinoma patients treated with
gemcitabine-based adjuvant chemotherapy after surgical resection.
Ann Surg 2012, 256:288–296.
21. Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y,
Tokunaga O, Noshiro H, Miyazaki K: Ribonucleotide reductase subunit M1
assessed by quantitative double-fluorescence immunohistochemistry
predicts the efficacy of gemcitabine in biliary tract carcinoma. Int J Oncol
2010, 37:845–852.
doi:10.1186/1477-7819-11-117
Cite this article as: Murata et al.: Prognostic predictive values of
gemcitabine sensitivity-related gene products for unresectable or
recurrent biliary tract cancer treated with gemcitabine alone. World
Journal of Surgical Oncology 2013 11:117.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
